Verastem reduces its workforce by 50%
9 October 2015 | By Victoria White
Verastem’s announcement comes just weeks after the company had to abandon enrolment in a Phase 2 study of its lead cancer drug VS-6063...
List view / Grid view
News
Eltrombopag shown to be effective in children with ITP
9 October 2015 | By Victoria White
The study demonstrate that eltrombopag is well tolerated and effective, consistently stabilising the platelet count to over 50 X 109 per litre within 2-6 weeks for 40% of children...
Ocrelizumab signficantly reduces disability progression in MS in studies
9 October 2015 | By Victoria White
Roche’s Chief Medical Officer said the results of the pivotal trials have the potential to transform the treatment of MS...
BI 655066 cleared skin better than ustekinumab in psoriasis study
8 October 2015 | By Victoria White
Boehringer Ingelheim has reported new results from a Phase II head-to-head psoriasis study that showed superior efficacy of the company’s biologic compound BI 655066 over ustekinumab...
FDA grants Fast Track designation to avelumab for Merkel cell carcinoma
8 October 2015 | By Victoria White
The designation relates to the clinical development programme for avelumab in metastatic MCC, which includes the Phase II study, JAVELIN Merkel 200...
Abemaciclib gets Breakthrough Therapy Designation
8 October 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to abemaciclib for patients with refractory HR+ advanced or metastatic breast cancer...
Lemtrada treatment effects maintained over five years in RRMS
8 October 2015 | By Victoria White
Lemtrada targets CD52, a protein abundant on T and B cells. Circulating T and B cells are thought to be responsible for the damaging inflammatory process in MS...
FDA grants HAE drug Ruconest 12-years of exclusivity
8 October 2015 | By Victoria White
The exclusivity ensures that the FDA will not approve any applications for biosimilars of the drug before July 2026...
Novartis releases long-term efficacy results for Gilenya in MS
8 October 2015 | By Victoria White
The analysis evaluated the proportion of Gilenya patients achieving 'no evidence of disease activity' (NEDA-4) every year over seven years...
NICE says ‘yes’ to pembrolizumab for advanced melanoma
7 October 2015 | By
Pembrolizumab was the first drug to be approved through the Medicines and Healthcare Products Regulatory Agency’s Early Access to Medicine Scheme (EAMS)...
Multiple sclerosis therapeutics market to reach $20b by 2024
7 October 2015 | By Victoria White
The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion by 2024...
New data shows sustained efficacy of Tecfidera in RRMS
7 October 2015 | By Victoria White
Biogen is to present the data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)...
FDA approves schizophrenia treatment Aristada
7 October 2015 | By Victoria White
Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection...
New data suggests Aubagio slows brain atrophy in RMS
7 October 2015 | By Victoria White
MRI data from Genzyme’s Phase III TEMSO study demonstrate that Aubagio significantly slowed brain atrophy in people with relapsing multiple sclerosis (RMS)...
AcelRx initiates Phase 3 study of pain treatment ARX-04
6 October 2015 | By Victoria White
AcelRx is developing ARX‑04 for the management of moderate-to-severe acute pain in a variety of medically supervised settings, including the emergency room...
